ABSORB trial Five year and Two year results for the Bioresorbable Vascular Scaffold(Abbott Vascular)

Positive long-term data are reported from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) from Abbott Vascular for the treatment of coronary artery disease. Five-year results from the first stage and two-year and 18-month data from the second stage of the ABSORB trial were recently presented at the 2011 American Heart Association's Scientific Sessions in Orlando and the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco. At five years, there were no reports of cardiac deaths, blood clots (thromboses) or ischemia-driven target lesion revascularization in the first stage of the ABSORB trial, which enrolled 30 patients. The major adverse cardiac event (MACE) rate at five years was 3.4 percent, with no new events reported between six months and five years. At two years, no blood clots and a MACE rate of 6.8 percent were reported in 44 patients from the second stage of the ABSORB trial.